EMVision Medical Devices (ASX:EMV) shipped an emu brain scanner to a second US pivotal validation trial site, the Mayo Clinic in Jacksonville, Florida, according to a Monday Australian bourse filing.
The site initiation visit and training are scheduled to begin in early May, the filing said.
The site initiation visit and device training visit at its first US site, the University of Texas Health Science Center at Houston Medical School and Memorial Hermann-Texas Medical Center, is scheduled for this week.
The primary goal of the trial is to demonstrate haemorrhage detection sensitivity and specificity of greater than 80%, supporting the device's registration with the US Food and Drug Administration.
It plans to initiate further trial sites in the US and Australia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。